December 23, 2008 — In the treatment of advanced ovarian cancer, neoadjuvant chemotherapy before surgical debulking may be the new standard of care — especially in countries where the scheduling of a ...

CHICAGO -- Upfront surgery for advanced ovarian cancer failed to improve overall survival (OS) versus interval debulking but did improve progression-free survival (PFS) for the first time in a phase ...

Significant disparities exist in the adoption of minimally invasive interval debulking surgery for advanced ovarian cancer, with gaps potentially widening as the procedure becomes more common.

Development and validation of a proteo-metabolic panel for detection of asymptomatic ovarian cancer with minimal serum sample requirements: A multi-center prospective study.

Ovarian cancer kills more women than any other gynecological cancer. Most patients receive their diagnosis only after the disease spreads throughout the abdomen. Until now, scientists have never fully ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant chemotherapy significantly lowered 90-day postoperative mortality for advanced ovarian cancer across ...

Fig 1. Summary of key NACT for advanced EOC recommendations. C, conditional; ECOG, Eastern Cooperative Oncology Group; EOC, epithelial ovarian cancer; H, high; ICS ...

Fuzuloparib monotherapy significantly improved PFS in advanced ovarian cancer, but adding apatinib did not enhance outcomes. The study included patients with newly diagnosed ovarian, fallopian tube, ...

Ovarian cancer lacks effective screening, making early detection difficult; symptoms are often non-specific and include bloating, early satiety, and abdominal pain. Diagnosis involves imaging, biopsy, ...